Results 251 to 260 of about 13,238,937 (304)

Arterial spin labeling MRI based perfusion pattern related to motor dysfunction and L-DOPA reactivity in Parkinson's disease. [PDF]

Neuroimage Clin
Zheng Q, Yuan W, Wen J, Qin J, Wu C, Wu H, Duanmu X, Tan S, Guo T, Zhou C, Wu J, Chen J, Zeng Q, Fang Y, Zhu B, Yan Y, Tian J, Zhang B, Zhang M, Guan X, Xu X.   +20 more
europepmc   +1 more source

Impulsive-compulsive behaviours and striatal neuroactivity in mildly parkinsonian rats under D2/3 agonist and L-DOPA treatment. [PDF]

NPJ Parkinsons Dis
Wolfschlag M, Espa E, Skovgård K, Halje P, Cenci MA.   +4 more
europepmc   +1 more source

Widespread and Heterologous Effects of L-DOPA on Monoaminergic Tissue Metabolism in Newborn Rats Expressing Air-Stepping. [PDF]

Int J Mol Sci
Barrière G, Pelloquin-Mvogo Z, Boulain M, Khsime I, Bharatiya R, Riquier MA, Morin D, Allain AE, Chagraoui A, Juvin L, De Deurwaerdere P.   +10 more
europepmc   +1 more source

Potential therapeutic effects of curcumin, with or without L-DOPA, on motor and cognitive functions and hippocampal changes in rotenone-treated rats. [PDF]

Metab Brain Dis
Belviranlı M, Okudan N, Sezer T.
europepmc   +1 more source

Neuroprotective effect of L-DOPA-induced interleukin-13 on striatonigral degeneration in cerebral ischemia. [PDF]

Cell Death Dis
Jeon E, Seo MS, Lkhagva-Yondon E, Lim YR, Kim SW, Kang YJ, Lee JS, Lee BD, Wi R, Won SY, Chung YC, Park ES, Kim E, Jin BK, Jeon MS.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

L-Dopa and Oligozoospermia

Andrologia, 2009
A clinical investigation of L-Dopa on idiopathic oligozoospermia is carried out. Thirty nine male oligozoospermic patients with primary sterility were divided in two groups. The first group of 25 patients was treated with 500 mg a day during two months. The second group of 14 patients received 750 mg a day for the same time.
J C, Lavieri, A A, Pierini
openaire   +2 more sources

L-Dopa and Parkinsonism

Nature, 1970
This new treatment for an old disease has its origins in pharmacological research of the late 1950s. There is still not full agreement about how L-dopa functions in the nervous system, but, as this review shows, there is ample evidence to support the clinical work in progress since 1961.
D B, Calne, M, Sandler
openaire   +2 more sources

l-dopa and pancreatic secretion

Biochemical Pharmacology, 1973
Abstract Greengard , Roback and Ivy (1942) first observed that epinine ( N -methyldopamine), dopamine (dihydroxyphenylethylamine) and few phenylethylamine derivatives given intravenously stimulated the canine pancreatic secretion, while the majority of sympathomimetic amines tested inhibited it.
KOROKU HASHIMOTO, YASUHIKO FURUTA, KAZUHIKO IWATSUKI   +2 more
openaire   +1 more source

Antispastic effects of l-dopa

Experimental Brain Research, 1996
Antispastic effects of the noradrenaline and dopamine precursor l-3,4-dihydroxyphelanine (L-dopa) were investigated in 11 subjects in which exaggerated stretch reflexes developed after spinal cord injuries. The effects were evaluated from changes in the electromyographic (EMG) response of the quadriceps muscle during tendon jerks evoked by standardized
J, Eriksson, B, Olausson, E, Jankowska
openaire   +2 more sources

Effect of L‐Dopa on Polycythemia

Journal of the American Geriatrics Society, 1977
ABSTRACT A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L‐dopa plus a decarboxylase inhibitor (Madopar).
Y, Herishanu, P, Rosenberg
openaire   +2 more sources